Latest 10-K annual reports

HA Sustainable Infrastructure Capital, Inc. filed an amendment to its 2025 Annual Report to include separate financial statements for significant unconsolidated subsidiaries, Palmetto HASI Holdings LLC and Daggett Renewable Holdco LLC, as required by SEC regulations.

Shoe Carnival reports a 5.6% net sales decrease in Fiscal 2025, with a strategic slowdown in its Shoe Station rebanner initiative despite strong gross profit margin expansion.

Pioneer Acquisition I Corp, a blank check company, filed its annual 10-K report for fiscal year 2025, detailing its post-IPO financial position and ongoing efforts to identify a business combination target, primarily in the healthcare sector.

Aptevo Therapeutics, a clinical-stage biotech, reported positive clinical data for its lead cancer candidates mipletamig and ALG.APV-527, while addressing ongoing financial challenges and securing additional capital.

Apex Treasury Corporation's annual report details its blank check company structure, IPO, and ongoing search for a business combination in target industries like blockchain, AI, and renewable energy.

Vroom, Inc. reports its 2025 annual results, highlighting its emergence from Chapter 11 bankruptcy, a strategic shift to auto finance and AI, and ongoing efforts to achieve profitability amidst increasing credit losses.

Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $50.2 million for 2025, narrowing losses while advancing its core transplant diagnostics and securing significant capital for future growth.

P3 Health Partners Inc. reports continued net losses and substantial doubt about its ability to continue as a going concern, despite efforts to raise capital and strategic adjustments.

Gain Therapeutics reports positive Phase 1b Parkinson's trial data for GT-02287 but acknowledges substantial doubt about its ability to continue as a going concern beyond Q1 2027.

Allegiant Travel Company files an amended 2025 annual report, highlighting record airline revenue, operational efficiency, and strategic corporate governance updates.

Lands End reports mixed Fiscal 2025 results, with declining net revenue but improved adjusted earnings, and announces a strategic intellectual property joint venture with WHP Global to repay its term loan.

Acumen Pharmaceuticals reported increased net losses for 2025 while advancing its lead Alzheimer's drug candidate, sabirnetug, and expanding its next-generation brain delivery platform.

Reliance Global Group, Inc. filed an amendment to its 2025 Annual Report on Form 10-K to include its Compensation Recovery Policy and updated certifications.

Spero Therapeutics achieved a net income of $8.6 million in 2025, driven by collaboration revenue, as it streamlines its pipeline to focus on the FDA approval process for tebipenem HBr with GSK.

Karbon Capital Partners Corp. (KBON) files its 10-K, outlining its blank check company structure, recent IPO, and strategy to acquire a business in the energy sector.

Dar Bioscience reported a significant net loss increase in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing its product pipeline and expanding commercial strategies.

TechnipFMC plc filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K to include inadvertently omitted director and officer signatures.

VirTra, Inc. announced a significant 15% decline in 2025 revenues to $22.4 million and an 81% drop in net income to $0.26 million, citing government funding delays and international delivery timelines.

TechnipFMC plc filed an amendment to its 2024 Annual Report on Form 10-K solely to include previously omitted signatures of its directors and officers.

Hoyne Bancorp, Inc. reported a net income of $233,000 for the year ended December 31, 2025, following its conversion to a stock form of ownership and successful $79.4 million stock offering.

Actuate Therapeutics' lead drug candidate, elraglusib, demonstrated a statistically significant improvement in median overall survival for metastatic pancreatic cancer in a Phase 2 trial.

Iris Acquisition Corp II, a blank check company, filed its annual report detailing its structure, search for a business combination, and financial position as of December 31, 2025.

FB Bancorp reported a significant increase in net income from continuing operations for 2025, driven by higher net interest income and the strategic divestiture of its loss-making mortgage banking segment.

The Dixie Group reported a reduced net loss and improved operating income for fiscal year 2025, but auditors and management express substantial doubt about the company's ability to continue as a going concern.

Oil States International, Inc. filed an amended annual report for 2025, correcting an auditor's report date while disclosing significant net losses and asset impairments.

Orgenesis Inc. reports substantial doubt about its ability to continue as a going concern, with significant net losses and a worsening working capital deficit, following its delisting from Nasdaq.

Linkhome Holdings Inc. reports significant revenue growth driven by its Cash Offer program in 2025, despite a substantial decrease in net income and gross profit, while highlighting its AI-driven real estate platform.

Sypris Solutions reported a significant increase in net loss for fiscal year 2025, driven by a downturn in its commercial vehicle segment and operational challenges in electronics.

MetaVia Inc. reported positive clinical trial results for its MASH and obesity drug candidates, vanoglipel (DA-1241) and DA-1726, but faces substantial doubt about its ability to continue as a going concern due to recurring net losses and a need for additional capital.

Marchex reports a 6% revenue decline in 2025 to $45.4 million, alongside increased net losses, while actively investing in AI-powered conversational intelligence and pursuing strategic acquisitions.